Investing
Payments To Acquired In-Process Research And Development Assets
Johnson & Johnson Payments To Acquired In-Process Research And Development Assets remained flat by 0.0% to $96.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 78.4%, from $445.75M to $96.25M.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ4 2025Feb 11, 2026
How to read this metric
Higher spending indicates a commitment to long-term growth through external R&D investment.
Detailed definition
This represents actual cash outflows directed toward the acquisition of research and development assets or projects. Unl...
Peer comparison
Common for large-cap pharmaceutical firms that rely on external partnerships for product development.
Metric ID:
investing_payments_to_acquired_in_process_research_and_d_39d004Historical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $470.00M | $1.78B | $385.00M |
| YoY Change | — | — | — | +279.4% | -78.4% |
Range$0.00 – $1.78B
Avg YoY Growth+100.5%
Median YoY Growth+100.5%
Payments To Acquired In-Process Research And Development Assets at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's payments to acquired in-process research and development assets?
- Johnson & Johnson (JNJ) reported payments to acquired in-process research and development assets of $96.25M in Q4 2025.
- How has Johnson & Johnson's payments to acquired in-process research and development assets changed year-over-year?
- Johnson & Johnson's payments to acquired in-process research and development assets decreased by 78.4% year-over-year, from $445.75M to $96.25M.
- What does payments to acquired in-process research and development assets mean?
- Cash spent to acquire external research and development projects.